Centronuclear Myopathies Drug Market Key Country Analysis - Audentes Therapeutics, Ionis Pharmaceuticals, Inc, Dynacure, Valerion Therapeutics

(CDN Newswire via Comtex)

The scope of this Global Centronuclear Myopathies Drug Market report includes in-depth insights of global and regional markets with the sense given for variation in the growth of the Pharmaceutical industry in certain regions. Few of the important factors that have been provided in this report includes the product cost structure, the manufacturing process, and product specification. Global Centronuclear Myopathies Drug Market report helps you understand the future outlook and prospects for Pharmaceutical industry analysis and forecast 2019-2026.

Global centronuclear myopathies drug market is growing at a steady CAGR in the forecast period of 2019-2026. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth.

Request Sample of Global Centronuclear Myopathies Drug Market Status and Future Forecast 2019-2026 @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-centronuclear-myopathies-drug-market

Key Developments in the Market:

In August 2019, Dynacure in a collaboation with Ionis Pharmaceuticals, Inc received Orphan Drug designation from the FDA for the treatment of Centronuclear Myopathies. With the Orphan Drug designation, companies can obtain financial incentives from the government along with 7 year period marketing exclusivity.

In November 2017, Ionis Pharmaceuticals, Inc. out-licensed worldwide development and commercialization right to Dyanacure for IONIS-DNM2-2.5Rx (Dyn101), a generation 2.5 antisense drug targeting dynamin 2 receptor for the treatment of centronuclear myopathy (CNM). Under the deal terms, Dyanacure paid USD 5.00 million as a licensee fee and eligible to pay additional cash of nearly USD 205.00 million as milestone payment. Additionally, Ionis Pharmaceuticals, Inc. is entitled to receive royalties on future net sales of the product. This collaboration provides potential treatment for patients suffering from centronuclear myopathy.

Competitive Analysis:

Global centronuclear myopathies drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Global centronuclear myopathies drug market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

  • Current and future of global centronuclear myopathies drug market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Enquire for customization in Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-centronuclear-myopathies-drug-market

Few of the major competitors currently working in the global centronuclear myopathies drug market are

Audentes Therapeutics,

Ionis Pharmaceuticals, Inc,

Dynacure,

Valerion Therapeutics,

Biophytis,

ARMGO Pharma Inc,

Stealth BioTherapeutics Inc and others.

Market Definition:

Centronuclear Myopathy is a rare genetic disease which primarily causes muscle weakness. The protein myotubularin which is essential for our ability to breathe and swallow is either missing or dysfunctional due to a mutation to the MTM1 gene. This protein is essential for our muscles to contract. Many patients with centronuclear myopathy need immediate intervention and need around-the-clock care including ventilator support in a feeding tube.

According to the statistics published in the Valerion Therapeutics, it was estimated the overall prevalence of this disease is 1: 50,000 male births. Huge financial support from the government and increase in strategic alliances between the companies are key factors for market growth.

Market Drivers

  • Family history of centronuclear myopathy is driving the market growth
  • Increase special designation from the regulatory authorities is boosting the market growth
  • High specific demand of novel treatment is accelerating the market growth
  • Huge financial support to the researchers for developing novel intervention is enhancing the market growth

Market Restraints

  • Limited availability of medicinal treatment options due to low prevalence of centronuclear myopathy is restraining the market growth
  • Fewer approvals of drugs from the regulatory authorities is hindering the market growth

Segmentation:

By Types

  • Myotubular Myopathy
  • Autosomal Centronuclear Myopathies
  • Others

By Treatment Type

  • Night Time Ventilation
  • Gastrostomy
  • Physiotherapy
  • Antibiotics
  • Others

By Diagnosis

  • Muscle Biopsy
  • Molecular Testing
  • Others

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retailers
  • Others

By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Global Centronuclear Myopathies Drug Market Table Of Content

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Global Centronuclear Myopathies Drug Market Landscape

Part 04: Global Centronuclear Myopathies Drug Market Sizing

Part 05: Global Centronuclear Myopathies Drug Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

View Detailed Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-centronuclear-myopathies-drug-market

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at [email protected].